Doxylamine, a first-generation antihistamine developed in the mid-20th century, was initially introduced for its sedative and anti-allergic properties. Over time, it became widely used as an over-the-counter sleep aid and, in combination with pyridoxine, as a treatment for nausea and vomiting in pregnancy (morning sickness). Its history is marked by its effectiveness in alleviating insomnia and pregnancy-related nausea, with a generally favorable safety profile when used as recommended. While Doxylamine is associated with sedation and anticholinergic side effects, serious adverse reactions are rare. It has been included in multiple combination formulations and continues to be a mainstay in both sleep aid products and pregnancy-related antiemetic therapy.
BRAND NAMES
Unisom® – commonly used as an over-the-counter sleep aid
Nytol® – another OTC formulation for insomnia
Diclegis® – combination with pyridoxine, used for nausea and vomiting in pregnancy.
MECHANISM OF ACTION
Doxylamine is a first-generation antihistamine that works primarily by blocking histamine H1 receptors in the central nervous system and peripheral tissues. By antagonizing H1 receptors, it reduces the effects of histamine, leading to sedation, anti-allergic effects, and decreased stimulation of the vomiting center in the brain. Its sedative action is due to crossing the blood-brain barrier and inhibiting histaminergic signaling in the central nervous system.
PHARMACOKINETICS
Absorption
Doxylamine is rapidly absorbed from the gastrointestinal tract after oral administration, with peak plasma concentrations typically reached within 2–3 hours. Its oral bioavailability is high, allowing effective systemic exposure even at standard over-the-counter doses.
Distribution
Doxylamine has a relatively large volume of distribution (Vd) of approximately 1–2 L/kg, reflecting its extensive distribution into body tissues, including the central nervous system, liver, and lungs.
Metabolism
Doxylamine is primarily metabolized in the liver through N-demethylation and hydroxylation, producing several inactive metabolites. The metabolism is mainly mediated by cytochrome P450 enzymes, which convert the drug into forms that are more easily excreted.
Elimination
Doxylamine is primarily eliminated via renal excretion of its metabolites, with only a small amount excreted unchanged in the urine. The drug has an approximate elimination half-life of 10–12 hours, which supports once-daily or bedtime dosing for its sedative effect.
PHARMACODYNAMICS
Doxylamine is a first-generation H1 histamine receptor antagonist that exerts its effects by blocking histamine at central and peripheral H1 receptors. This receptor blockade leads to sedation, reduction of allergic symptoms, and antiemetic effects. In the central nervous system, Doxylamine crosses the blood-brain barrier, where it inhibits histaminergic signaling in the reticular activating system, producing pronounced sleep-inducing effects.
ADMINISTRATION
Doxylamine is administered orally, available in tablets, capsules, and combination formulations with pyridoxine for pregnancy-related nausea. For insomnia, the typical adult dose is 10 mg at bedtime, taken with a full glass of water.
DOSAGE AND STRENGTH
Doxylamine is available in oral tablets or capsules of 10 mg, and in combination with pyridoxine for pregnancy-related nausea (e.g., Diclegis®), typically containing 10 mg Doxylamine and 10 mg pyridoxine per tablet. For insomnia, the usual adult dose is 10 mg orally at bedtime, which may be adjusted based on response and tolerance.
DRUG INTERACTIONS
Doxylamine may interact with drugs that enhance sedation or CNS depression, including alcohol, benzodiazepines, opioids, barbiturates, and other antihistamines, leading to excessive drowsiness, dizziness, or respiratory depression.
FOOD INTERACTIONS
Doxylamine absorption is not significantly affected by food, so it can be taken with or without meals. However, taking it with alcohol or other central nervous system (CNS) depressants can enhance sedation, drowsiness, and impairment of alertness. Patients are advised to avoid alcohol while using Doxylamine to minimize these additive sedative effects.
CONTRAINDICATIONS
Doxylamine is contraindicated in patients with known hypersensitivity to Doxylamine or other first-generation antihistamines. It should not be used in newborns or premature infants due to the risk of excessive sedation and respiratory depression. Caution is advised in patients with severe asthma, chronic obstructive pulmonary disease (COPD), or other respiratory conditions, as Doxylamine’s sedative and anticholinergic effects may worsen breathing.
SIDE EFFECTS
Drowsiness and sedation
Dry mouth, throat, or nose
Dizziness or lightheadedness
Headache
Mild gastrointestinal discomfort.
OVER DOSAGE
Overdosage of Doxylamine can occur due to accidental ingestion, especially in children, or intentional overdose, leading to pronounced CNS depression, extreme drowsiness, confusion, agitation, hallucinations, seizures, and, in severe cases, coma. Anticholinergic symptoms such as dry mouth, urinary retention, tachycardia, and flushed skin are common.
TOXICITY
Doxylamine toxicity usually results from accidental or intentional overdose and primarily affects the central nervous system and cardiovascular system. Symptoms of toxicity include extreme drowsiness, confusion, agitation, hallucinations, seizures, and respiratory depression. Anticholinergic effects such as dry mouth, dilated pupils, urinary retention, and tachycardia may also occur.
